Serina Therapeutics Inc

SER

Add to Watchlist

1.640USD

-0.080-4.65%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Serina Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

181 / 382

Overall Ranking

328 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Serina Therapeutics Inc Highlights

StrengthsRisks

Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.

Growing

The company is in a growing phase, with the latest annual income totaling USD 130.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 130.00K.

Overvalued

The company’s latest PE is -0.83, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.62M shares, increasing 40.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

13.000

Target Price

+655.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Serina Therapeutics Inc is 6.04, ranking 290 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.04

Change

0



Financials

6.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.60

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Serina Therapeutics Inc is 6.33, ranking 285 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.83, which is -649.72% below the recent high of 4.59 and -704.34% above the recent low of -6.71.

Score

Industry at a Glance

Previous score

6.33

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 181/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Serina Therapeutics Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 15.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Serina Therapeutics Inc is 4.34, ranking 346 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.00 and the support level at 1.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.45

Change

-0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Serina Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.86%, representing a quarter-over-quarter increase of 154.48%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Juvenescence Ltd

3.27M

--

Puffinus L.P.

904.88K

--

McMillan (Helen w)

708.61K

-15.88%

Bailey (Gregory Hugh)

67.24K

--

Ledger (Steven A)

95.73K

-70.42%

Waverly Advisors, LLC

67.49K

--

Broadwood Capital, Inc.

54.48K

-34.51%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Serina Therapeutics Inc is 2.03, ranking 248 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Serina Therapeutics Inc

SER

5.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment